Hinge Health IPO後首份財報耀眼 盤後勁漲7%
美國數位醫療新創公司Hinge Health（HNGE.US）揭曉IPO上市以來首份財報，受惠AI智慧醫療商機興起，上季營收強勁成長55%，激勵盤後股價躍升逾7%。
根據Hinge Health 8月5日盤後公告的財報資料，2025年第二季（截至2025年6月30日），營收大幅年增55%至1.39億美元，超越LSEG共識預期的1.25億美元；但淨損擴大至5.7565億美元、即每股虧損13.10美元，遠高於去年同期的1,293萬美元、即每股虧損0.96美元。
依據一般公認會計準則（GAAP），第二季營業虧損為5.807億美元，其中包括公司以股票獎酬員工，需認列薪資費用5.91億美元。
展望第三季，Hinge Health預估營收可達1.41億美元至1.43億美元，優於LSEG平均預期的1.29億美元；全年營收預計為5.48億美元至5.52億美元，亦超出LSEG調查所預期的5.11億美元。
Yahoo Finance報價顯示，8月5日正常盤Hinge Health收48.22美元，股價持平，盤後強勢大漲7.84%至52.00美元。
Hinge Health成立於2014年，主要產品是骨骼肌肉數位照護平台，透過科技及數據分析，為病患量身打造居家醫療計畫，結合穿戴式裝置，在家完成客製化的遠端復健療程，減少疼痛並改善生活品質。
5月22日，Hinge Health在紐約證交所掛牌上市，在投資人蜂擁搶進下，盤中最高衝上40.26美元，終場收在37.56美元，較IPO發行價32美元勁揚17.38%。
（圖片來源：Hinge Health）
＊編者按：本文僅供參考之用，並不構成要約、招攬或邀請、誘使、任何不論種類或形式之申述或訂立任何建議及推薦，讀者務請運用個人獨立思考能力，自行作出投資決定，如因相關建議招致損失，概與《精實財經媒體》、編者及作者無涉。
延伸閱讀：
UI設計軟體商Figma具AI潛力 掛牌首日暴漲250%
Figma IPO募集12億美元銀彈 31日正式掛牌
資料來源-MoneyDJ理財網
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Heartflow stock listing and IPO date draw near: AI-powered medtech aims for $1.3 billion valuation
It seems there's fresh blood pumping back into the IPO market. After a blowout initial public offering from Figma last week, investors might have another chance to get their heart rates up again soon. AT&T to pay $177 million in data breach settlement. Here's how to claim up to $5,000 Wells Fargo is rolling out company wide AI. It says everyone from branch tellers to investment bankers will benefit Want to get smarter? Neuroscience says 5 simple steps significantly boost memory, learning, and cognition Heartflow, a California-based medtech company that utilizes AI with imaging and diagnostics software to help evaluate cardiac and coronary diseases, is looking to list shares on the Nasdaq. In paperwork filed on Friday with the Securities and Exchange Commission (SEC), Heartflow said it plans to offer 12.5 million shares, priced between $15 and $17. That could potentially raise more than $208 million. According to Reuters, Heartflow's target valuation could be as high as $1.3 billion. The company plans to trade under the ticker 'HTFL.' Personalized 3D-models of people's hearts Heartflow uses AI and other technology to scan patients for coronary and cardiac problems, creating three-dimensional models of patients' hearts. The Food and Drug Administration (FDA) gave the software the green light in 2022, and it's now being used in some markets to diagnose patients. Additionally, the company got a leg up last year when the U.S. Centers for Medicare and Medicaid Services (CMS) expanded Medicare coverage to include platforms that use imaging results to look for signs of coronary disease, and the American Medical Association (AMA) issued a new Category I CPT code for those platforms. That gives doctors and clinics the go-ahead to start using the technology on a broader scale starting next year. According to the company's SEC filing, Heartflow says that as of the end of March 2025, it's been used to assess more than 400,000 patients. Revenues are growing but profits are elusive Heartflow generated $125.8 million in 2024, a 44% increase over the $87.2 million it made the year before, the company says. Revenue likewise grew 39% for the first quarter of 2025 to $37.2 million. However, the company saw a net loss of $96.4 million in 2024, wider than its net loss of $95.7 million in 2023. It warns in the filing that it expects to incur 'substantial losses in the foreseeable future [and] may not be able to achieve or sustain profitability.' Bain Capital, Panorama Point Partners, and Capricorn Investment Group are among Heartflow's backers, according to Crunchbase. Bain led its most recent fundraising round, a Series F round in 2023, which raised $215 million. This is not the first time that Heartflow has attempted to go public. The company had planned to merge with a special purpose acquisition company during the SPAC frenzy of the early pandemic years, but it halted the plan in 2022, citing 'unfavorable market conditions,' as Fierce Biotech reported. Heartflow's IPO comes on the heels of another growing medtech company's public debut. Carlsmed, which specializes in AI-driven spine surgery technology, recently went public as well, with shares trading on July 23. Since then, the stock is down around 4.5%. Heartflow has not said when it plans to list its stock, although IPO calendar websites say the listing is expected this week. The company declined to comment on the timeline when reached by Fast Company. This post originally appeared at to get the Fast Company newsletter: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Sony reports Q1 profit up 36.5%, beating estimates
TOKYO (Reuters) -Sony on Thursday reported a 36.5% rise in operating profit in the April-June quarter, beating analyst estimates. Operating profit was 340 billion yen ($2.30 billion). That compared with an estimate of 288 billion yen from eight analysts polled by LSEG. ($1 = 147.5400 yen) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
an hour ago
- CNBC
Sony hikes annual profit forecast by 4%, citing smaller trade war impact
Sony raised its full-year operating profit forecast Thursday by 4% to 1.33 trillion yen ($9.01 billion), citing a diminished impact from U.S. President Donald Trump's trade war. In May, Sony forecast a profit of 1.28 trillion yen, factoring in a 100 billion yen hit from the tariffs. The Japanese conglomerate has transformed from a maker of household electronics such as the Walkman to an entertainment behemoth spanning games, movies, music and chips. Sony reported a 36.5% rise in operating profit to 340 billion yen for the April-June quarter, beating an estimate of 288 billion yen from eight analysts surveyed by LSEG.
